Sanofi Shares Rise on Strong 1Q -- Update
26 Avril 2019 - 10:52AM
Dow Jones News
By Donato Paolo Mancini
Shares in French pharmaceuticals giant Sanofi SA (SAN.FR) soared
in early trading Friday, after it posted net profit and sales
increases alongside an EPS beat for the first quarter, underpinned
by the gains reaped from investment in specialty care.
At 0819 GMT Paris-traded shares were up 3.7% at EUR76.39.
Analysts at Citi said the quarterly result was solid, noting the
9% beat in earnings per share as well as other notable beats in
vaccines and in Sanofi's oncology and rare-disease franchise. Citi
expects the growth outlook for the Paris-based company will
improve, as its collaboration with Regeneron Inc. (REGN) becomes
more profitable and headwinds in the diabetes market abate. The
bank has Sanofi stock among its favorite picks.
Business net income, an important adjusted net profit metric for
the French pharma company, was 1.77 billion euros ($1.97 billion),
or EUR1.42 a share, up 9% at constant exchange rates. IFRS net
profit was EUR1.14 billion, or EUR0.91 a share.
Sanofi backed its outlook for the 2019 business EPS, still
expecting 3% to 5% growth.
Sales were EUR8.39 billion, buoyed by specialty care and
vaccines. Analysts had expected sales of EUR8.45 billion. Sales in
the diabetes franchise declined 6.9%. The United States accounted
for 30% of the company's revenue in the first-quarter.
Indeed, as major pharma players refocus efforts on higher-value
drugs, including specialty-care medicines, market participants
worry whether companies will be ready to react and adapt to U.S.
health-care sector changes floated by the Democratic Party as
presidential elections loom next year. Public discourse has so far
mainly hinged on pricing and, Sanofi, with its exposure to the
U.S., could be affected by any structural changes.
"We are very vocal and clear about our pricing strategy in the
U.S.," Chief Financial Officer Jean-Baptiste de Chatillon said in a
call with reporters Friday.
"We are not expecting anything major that is not already known
and described in the last communications we made about this," he
said when asked whether the company was positioning itself
strategically in terms of any structural health-care reform in the
U.S.
A spokesman later Friday said Sanofi recently participated in
Senate and House committee hearings on the issue, and that its
price increases are at or below the U.S. National Health
Expenditure projected growth rate. Sanofi cut the price of one of
its insulins for certain patients with diminished access to $99 a
month, hours before one of its executives testified in Congress
earlier this month.
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
April 26, 2019 04:37 ET (08:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024